BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35990639)

  • 1. Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection.
    Abu Shanap M; Sughayer M; Alsmadi O; Elzayat I; Al-Nuirat A; Tbakhi A; Sultan I
    Front Immunol; 2022; 13():919762. PubMed ID: 35990639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroconversion in hematology-oncology patients.
    Bird PW; Badhwar V; Kennedy B; Ladani S; Tang JW
    J Med Virol; 2021 Jul; 93(7):4585-4591. PubMed ID: 33595119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
    Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
    J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Seroconversion in Children and Adults With Mild COVID-19.
    Toh ZQ; Anderson J; Mazarakis N; Neeland M; Higgins RA; Rautenbacher K; Dohle K; Nguyen J; Overmars I; Donato C; Sarkar S; Clifford V; Daley A; Nicholson S; Mordant FL; Subbarao K; Burgner DP; Curtis N; Bines JE; McNab S; Steer AC; Mulholland K; Tosif S; Crawford NW; Pellicci DG; Do LAH; Licciardi PV
    JAMA Netw Open; 2022 Mar; 5(3):e221313. PubMed ID: 35262717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
    Guven DC; Sahin TK; Akın S; Uckun FM
    Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates.
    Lodde GC; Fiedler M; Dittmer U; Placke JM; Jansen P; Becker JC; Zimmer L; Livingstone E; Schadendorf D; Sondermann W; Ugurel S
    Front Oncol; 2022; 12():879876. PubMed ID: 36091146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global characteristics and outcomes of SARS-CoV-2 infection in children and adolescents with cancer (GRCCC): a cohort study.
    Mukkada S; Bhakta N; Chantada GL; Chen Y; Vedaraju Y; Faughnan L; Homsi MR; Muniz-Talavera H; Ranadive R; Metzger M; Friedrich P; Agulnik A; Jeha S; Lam C; Dalvi R; Hessissen L; Moreira DC; Santana VM; Sullivan M; Bouffet E; Caniza MA; Devidas M; Pritchard-Jones K; Rodriguez-Galindo C;
    Lancet Oncol; 2021 Oct; 22(10):1416-1426. PubMed ID: 34454651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center.
    Freeman MC; Rapsinski GJ; Zilla ML; Wheeler SE
    J Pediatric Infect Dis Soc; 2021 Apr; 10(4):426-431. PubMed ID: 33049042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Response to SARS-CoV-2 Infections in Children with Secondary Immunodeficiencies.
    Kuczborska K; Krzemińska E; Buda P; Heropolitańska-Pliszka E; Piątosa B; Książyk J
    J Clin Immunol; 2023 Jan; 43(1):57-64. PubMed ID: 36149567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2.
    Marra A; Generali D; Zagami P; Cervoni V; Gandini S; Venturini S; Morganti S; Passerini R; Orecchia R; Curigliano G
    Ann Oncol; 2021 Jan; 32(1):113-119. PubMed ID: 33098994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
    Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
    Front Immunol; 2022; 13():911738. PubMed ID: 35844596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 Vaccine Response in People with Multiple Sclerosis.
    Tallantyre EC; Vickaryous N; Anderson V; Asardag AN; Baker D; Bestwick J; Bramhall K; Chance R; Evangelou N; George K; Giovannoni G; Godkin A; Grant L; Harding KE; Hibbert A; Ingram G; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Schmierer K; Scurr MJ; Shah SN; Simmons J; Upcott M; Willis M; Jolles S; Dobson R
    Ann Neurol; 2022 Jan; 91(1):89-100. PubMed ID: 34687063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors Affecting Side Effects, Seroconversion Rates and Antibody Response After Inactivated SARS-CoV-2 Vaccination in Healthcare Workers].
    Şenol Akar Ş; Akçalı S; Özkaya Y; Gezginci FM; Cengiz Özyurt B; Deniz G; Karadağ Yalçın F; Özer D; Dündar Erbay P; Eser E
    Mikrobiyol Bul; 2021 Oct; 55(4):519-538. PubMed ID: 34666653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody Response and Safety After mRNA-1273 SARS-CoV-2 Vaccination in Peritoneal Dialysis Patients - the Vienna Cohort.
    Beilhack G; Monteforte R; Frommlet F; Gaggl M; Strassl R; Vychytil A
    Front Immunol; 2021; 12():780594. PubMed ID: 34925359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of SARS-CoV-2 Antibody Responses and Seroconversion in COVID-19 Patients Using Twelve Commercial Immunoassays.
    Yun S; Ryu JH; Jang JH; Bae H; Yoo SH; Choi AR; Jo SJ; Lim J; Lee J; Ryu H; Cho SY; Lee DG; Lee J; Kim SC; Park YJ; Lee H; Oh EJ
    Ann Lab Med; 2021 Nov; 41(6):577-587. PubMed ID: 34108285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High anti-SARS-CoV-2 antibody seroconversion rates before the second wave in Manaus, Brazil, and the protective effect of social behaviour measures: results from the prospective DETECTCoV-19 cohort.
    Lalwani P; Araujo-Castillo RV; Ganoza CA; Salgado BB; Pereira Filho IV; da Silva DSS; de Morais TBDN; Jordão MF; Ortiz JV; Barbosa ARC; Sobrinho WBS; Cordeiro IB; de Souza Neto JN; de Assunção EN; da Costa CF; de Souza PE; de Albuquerque BC; Astofi-Filho S; ; Lalwani JDB
    Lancet Glob Health; 2021 Nov; 9(11):e1508-e1516. PubMed ID: 34678195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.